Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM2520 in advanced solid tumors
NCT05780307Phase 1Unknown
- Sponsor
- ImmuneOnco
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Bispecific Antibodies, Receptor-Fc Fusions
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMM2520 in solid tumor (advanced stage), esophageal cancer and urothelial carcinoma (UC), sponsored by ImmuneOnco. Primary endpoints: Adverse Events, Dose-Limiting Toxicity and 6 more. Status: unknown.
02
Drugs
IMM2520
03
Conditions
solid tumor (advanced stage)esophageal cancerurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05780307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780307.